EBMT 2020 | CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies

Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, outlines the use of CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies, including the results of a first-in-man study of CD5 CAR T-cells in the treatment of T-cell malignancies, as well as challenges associated with bringing these innovative therapies to the clinic. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).